Is SYRE or TBPH more undervalued in 2026?

CirclFi compares Spyre Therapeutics, Inc. (SYRE) and Theravance Biopharma, Inc. (TBPH) using 13 institutional-grade valuation models. SYRE has a Quality of Company score of 5.4/10 while TBPH scores 8.4/10.

Which is a better buy — SYRE or TBPH?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SYRE and TBPH valuations compare?

SYRE at $72.11 and TBPH at $16.21 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SYRE vs TBPH Valuation Comparison 2026 — Intrinsic Value Analysis

SYRE

Biotechnology

Spyre Therapeutics, Inc.

Quality

5.4

out of 10

Value Trap

SAFE

Price

$72.11

Last close

Models

12/13

Active

TBPH

Biotechnology

Theravance Biopharma, Inc.

Quality

8.4

out of 10

Value Trap

SAFE

Price

$16.21

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	SYRE Fair Value	SYRE Upside	TBPH Fair Value	TBPH Upside
Bayesian DCF	Intrinsic	$22.23	-69.2%	—	—
Earnings Power Value	Intrinsic	$30.32	-56.5%	$10.88	-35.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$2.15	-97.1%	$4.67	-71.2%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SYRE vs TBPH — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SYRE vs TBPH — Which Stock Is More Undervalued?

TBPH scores higher with a 8.4/10 quality rating vs SYRE's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Spyre Therapeutics, Inc. (SYRE) and Theravance Biopharma, Inc. (TBPH) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SYRE currently trades at $72.11 with a QOC of 5.4/10, while TBPH trades at $16.21 with a QOC of 8.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).